Ibnsina Pharma Income Statement

Financials in millions EGP. Fiscal year is January - December.

Millions EGP. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	72,835	55,842	33,949	22,264	21,733	18,679
Revenue Growth (YoY)	50.03%	64.49%	52.48%	2.45%	16.35%	12.52%
Cost of Revenue	66,704	51,446	31,434	20,648	20,103	17,212
Gross Profit	6,131	4,397	2,515	1,617	1,630	1,467
Selling, General & Admin	2,569	1,931	1,289	1,076	829.22	822.71
Amortization of Goodwill & Intangibles	-	-	-	-	2.75	1.91
Other Operating Expenses	-57.16	-7.71	-9.46	-7	-	-
Operating Expenses	2,800	2,139	1,364	1,135	962.17	978.17
Operating Income	3,331	2,258	1,152	482.22	667.35	488.69
Interest Expense	-2,488	-1,686	-1,044	-477.09	-284.18	-255.32
Interest & Investment Income	-	0.2	-	-	-	-
Currency Exchange Gain (Loss)	14.56	55.35	38.53	38.41	0.28	-0.3
Other Non Operating Income (Expenses)	86.67	71.67	121.65	131.01	86.01	56.73
EBT Excluding Unusual Items	944.35	698.77	267.75	174.55	469.46	289.8
Gain (Loss) on Sale of Investments	1.56	1.56	-1.13	-	-	-
Gain (Loss) on Sale of Assets	2.95	2.95	1.39	0.75	4.25	2.42
Legal Settlements	-	-	-	-	-48	-
Other Unusual Items	-	-	-	-	-0.37	-
Pretax Income	948.87	703.28	268.02	175.31	425.34	292.22
Income Tax Expense	80.98	88.72	54.74	4.43	110.95	67.56
Earnings From Continuing Operations	867.89	614.56	213.27	170.87	314.4	224.66
Minority Interest in Earnings	-0	0	0.39	1.71	0.33	-
Net Income	867.89	614.56	213.66	172.58	314.73	224.66
Preferred Dividends & Other Adjustments	164.9	116.77	40.52	36.95	28.4	40.55
Net Income to Common	702.99	497.8	173.14	135.63	286.33	184.11
Net Income Growth	94.53%	187.63%	23.80%	-45.16%	40.09%	-31.67%
Shares Outstanding (Basic)	1,008	1,008	1,008	1,008	1,302	1,120
Shares Outstanding (Diluted)	1,008	1,008	1,008	1,008	1,302	1,120
Shares Change (YoY)	-	-	-	-22.58%	16.25%	-
EPS (Basic)	0.70	0.49	0.17	0.13	0.22	0.16
EPS (Diluted)	0.70	0.49	0.17	0.13	0.22	0.16
EPS Growth	94.53%	187.51%	27.65%	-38.81%	33.78%	-31.67%
Free Cash Flow	-3,288	-1,187	-228.23	-436.58	-487.96	21.75
Free Cash Flow Per Share	-3.26	-1.18	-0.23	-0.43	-0.38	0.02
Dividend Per Share	0.160	0.160	-	-	0.086	-
Gross Margin	8.42%	7.87%	7.41%	7.26%	7.50%	7.85%
Operating Margin	4.57%	4.04%	3.39%	2.17%	3.07%	2.62%
Profit Margin	0.97%	0.89%	0.51%	0.61%	1.32%	0.99%
Free Cash Flow Margin	-4.52%	-2.13%	-0.67%	-1.96%	-2.25%	0.12%
EBITDA	3,482	2,391	1,266	596.27	784.78	601.49
EBITDA Margin	4.78%	4.28%	3.73%	2.68%	3.61%	3.22%
D&A For EBITDA	150.96	133.16	114.18	114.04	117.43	112.8
EBIT	3,331	2,258	1,152	482.22	667.35	488.69
EBIT Margin	4.57%	4.04%	3.39%	2.17%	3.07%	2.62%
Effective Tax Rate	8.53%	12.62%	20.42%	2.53%	26.08%	23.12%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.